Medical versus surgical treatment of first trimester spontaneous abortion: A cost-minimization analysis

• Published in: PloS one 2019-01, Vol.14 (1), p.e0210449-e0210449
• Main Authors: Cubo, Ana M, Soto, Zandra M, Haro-Pérez, Ana, Hernández Hernández, M Estrella, Doyague, M José, Sayagués, José M
• Format: Article
• Language: English
• Subjects: Abortifacient Agents, Nonsteroidal - economics; Abortifacient Agents, Nonsteroidal - therapeutic use; Abortion; Abortion, Spontaneous - economics; Abortion, Spontaneous - surgery; Abortion, Spontaneous - therapy; Adult; Analysis; Birth control; Clinical trials; Comparative analysis; Cost analysis; Cost control; Cost engineering; Costs and Cost Analysis; Curettage; Decision trees; Engineering and Technology; Evacuation; Experimental research; Female; Gynecology; Health aspects; Health care; Health services; Hemoglobin; Hospitals; Humans; Internet; Longitudinal Studies; Medical treatment; Medicine and Health Sciences; Miscarriage; Misoprostol; Misoprostol - economics; Misoprostol - therapeutic use; Obstetrics; Optimization; Patients; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Research and Analysis Methods; Side effects; Stability; Studies; Surgery; Therapeutics; Ultrasonic imaging; Ultrasound; Uterus; Vagina
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0210449

Traditionally the gold-standard technique for the treatment of spontaneous abortion has been uterine evacuation by aspiration curettage. However, many studies have proposed medical treatment with misoprostol as an alternative to the conventional surgical treatment. The aim of this study was to apply cost minimization methods to compare the cost and effectiveness of the use of vaginal misoprostol as a medical treatment for first trimester spontaneous abortion with those of evacuation curettage as a surgical treatment. We present a longitudinal, prospective and quasi-experimental research study including a total of 547 patients diagnosed with first-trimester spontaneous abortion, in the period from January 2013 to December 2015. Patients were offered medical treatment with 800 mg vaginal misoprostol or evacuation curettage. Patients treated with misoprostol were followed-up at 7 days and a transvaginal ultrasound was performed to confirm the success of the treatment. If it failed, a second dose of 800 mg of vaginal misoprostol was prescribed and a new control ultrasound was performed. In case of failure of medical treatment after the second dose of misoprostol, evacuation curettage was indicated. The effectiveness of each of the treatment options was calculated using a decision tree. The cost minimization study was carried out by weighting each cost according to the effectiveness of each branch of the treatment. Of the 547 patients who participated in the study, 348 (64%) chose medical treatment and 199 (36%) chose surgical treatment. The overall effectiveness of medical treatment was 81% (283/348) and surgical treatment of 100%. The estimated final cost for medical treatment was € 461.92 compared to € 2038.72 for surgical treatment, which represents an estimated average saving per patient of € 1576.8. Medical treatment with misoprostol is a cheaper alternative to surgery: in the Spanish Public Healthcare System, it is five times more inexpensive than curettage. Given its success rates higher than 80%, mild side effects, controllable with additional medication and the high degree of overall satisfaction, it should be prioritized over the evacuation curettage in patients who meet the treatment criteria.